Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology

Does Von Willebrand Disease Affect Life Expectancy?

At a Glance

Having Von Willebrand Disease (VWD) does not shorten your life expectancy. While it is a lifelong bleeding disorder, modern treatments like desmopressin and factor replacement therapies effectively manage symptoms. With proper medical care, most people with VWD live full, active, and long lives.

In this answer

3 sections

01

Your Outlook Depends on Your Type

02

The Role of Modern Medicine

03

Protecting Your Long-Term Health

Being diagnosed with a lifelong condition like Von Willebrand Disease (VWD) naturally brings up questions about your long-term outlook, including worries about your life expectancy. The most important thing to know is that having VWD does not mean you will have a shorter lifespan. While researchers note a lack of large studies directly comparing VWD mortality to the general public [1], the medical consensus is clear: for the vast majority of people with VWD, life expectancy is considered normal.

VWD is the most common inherited bleeding disorder, and while the bleeding symptoms can be unpredictable and frustrating, they are generally mild to moderate [2][3]. With proper management and modern medical care, people with VWD live full, active, and long lives [4].

Your Outlook Depends on Your Type

VWD is not a one-size-fits-all condition. How it affects your daily life and long-term health depends mostly on which type you have [5].

Types 1 and 2: Highly Manageable

If you have Type 1 or Type 2 VWD, you are in the majority. These forms of the disease are typically mild to moderate [2]. Most people with Type 1 or Type 2 do not require daily continuous treatment [6].

However, treatment approaches differ between these types:

  • Type 1: Your doctor will likely prescribe desmopressin (DDAVP), a medication that temporarily boosts your body’s own clotting factors, for high-risk situations like surgery, dental work, or childbirth [7][8].
  • Type 2: This type is more complex. DDAVP often does not work for Type 2, and for some specific subtypes (like Type 2B), it can actually be unsafe [8]. Therefore, Type 2 is often managed with factor replacement therapies instead [7].

For women, heavy menstrual bleeding is often the most significant and disruptive symptom [9]. Managing menstruation and preventing iron-deficiency anemia is a critical part of maintaining a healthy, active outlook and good quality of life [10]. Overall, because these bleeding risks are managed so effectively on an as-needed basis, your life expectancy is not impacted.

Type 3: Severe but Treatable

Type 3 VWD is the most severe and rarest form of the disease. In Type 3, your body produces almost no Von Willebrand factor (VWF), which is the protein that helps blood clot [5][11]. Without treatment, this can lead to frequent and severe bleeding, including bleeds into the digestive tract or the joints [12][13]. Joint bleeds are particularly dangerous because repeated bleeding damages cartilage and can lead to permanent joint disease and chronic pain [14].

However, even for Type 3, the long-term outlook is incredibly positive thanks to modern medicine. People with Type 3 often use long-term prophylaxis, which involves taking regular infusions of treatments to prevent bleeding before it starts [15][16]. By staying on a consistent preventative treatment plan, people with severe VWD can avoid life-threatening complications and protect their joints from long-term damage, allowing them to lead long, healthy lives [14].

The Role of Modern Medicine

The reason the long-term outlook for VWD is so reassuring today is because of massive advancements in bleeding disorder treatments [17].

  • Factor Replacement Therapies: These treatments replace the missing clotting proteins in your blood using plasma-derived or recombinant (lab-made) VWF [18][19]. These therapies have drastically improved the ability to quickly and safely stop bleeding episodes or get patients through major surgeries [20][21].
  • Antifibrinolytics: Medications like tranexamic acid help prevent blood clots from breaking down [9]. They are incredibly common, non-factor therapies used for mucosal bleeds, dental work, and heavy menstruation [10].
  • Hemophilia Treatment Centers (HTCs): For long-term care, especially if you have a more severe form of VWD, your health is best protected by visiting a specialized Hemophilia Treatment Center. These centers provide comprehensive, multidisciplinary care that helps manage all aspects of your health over your lifetime [22][23].

Protecting Your Long-Term Health

While VWD does not shorten your lifespan, staying healthy requires some day-to-day mindfulness. One critical safety habit is to avoid over-the-counter pain medications that act as blood thinners, such as aspirin and NSAIDs (like ibuprofen or naproxen) [24][6]. These medications can trigger unexpected or severe bleeds [24]. Always check with your medical team before taking new medications.

While living with VWD requires you to be mindful of your health and stay connected with your medical team, it is a highly manageable condition. Being diagnosed is the first step toward getting the care you need to protect your future.

Common questions in this guide

Can You Develop Von Willebrand Disease Later in Life?Can You Get an Epidural with Von Willebrand Disease?Can You Have Iron Deficiency Without Anemia in VWD?Can You Play Sports with Von Willebrand Disease?Does Stress Affect Von Willebrand Disease Test Results?How Do Antifibrinolytics Work for VWD Bleeding?How Does Type O Blood Affect Von Willebrand Disease?How Is Von Willebrand Disease Inherited?Dental Work with Von Willebrand Disease: How to PrepareIs an IUD Safe for Women with Von Willebrand Disease?What Causes Delayed Postpartum Hemorrhage in VWD?What is a DDAVP Challenge Test for Von Willebrand Disease?What Is a Heavy Period with Von Willebrand Disease?Low VWF vs. Type 1 VWD: What is the Difference?Type 2N VWD vs. Hemophilia A: What's the Difference?What Pain Meds Are Safe for Von Willebrand Disease?What's in a VWD Emergency Travel Letter?When Are Nosebleeds a Sign of Von Willebrand Disease?Why Must I Restrict Fluids After DDAVP?
Is Von Willebrand Disease fatal?
For the vast majority of people, Von Willebrand Disease is not fatal and does not shorten life expectancy. With proper management and modern treatments, most people with the condition live full, active, and long lives.
How does the type of Von Willebrand Disease affect my prognosis?
Types 1 and 2 are generally mild to moderate and managed on an as-needed basis, having no impact on your life expectancy. Type 3 is more severe and carries a higher risk of dangerous bleeding, but regular preventative treatments allow patients to maintain a normal, healthy lifespan.
What medications should I avoid if I have Von Willebrand Disease?
You should avoid over-the-counter pain medications that act as blood thinners, such as aspirin and NSAIDs like ibuprofen or naproxen. These medications can trigger unexpected or severe bleeding episodes, so always check with your doctor before taking new pain relievers.
What treatments are available for severe Von Willebrand Disease?
For severe cases, such as Type 3, doctors often use long-term prophylaxis. This involves taking regular infusions of factor replacement therapies to replace missing clotting proteins, which prevents bleeding before it starts and protects your joints from permanent damage.
How is heavy menstrual bleeding managed with this condition?
Heavy menstrual bleeding is often managed with treatments like desmopressin or antifibrinolytic medications such as tranexamic acid, which help prevent blood clots from breaking down. Managing these bleeds is critical to preventing iron-deficiency anemia and maintaining your daily quality of life.

Questions for Your Doctor

5 questions

  • •What specific type of VWD do I have, and how does that influence which treatments will be safe and effective for me?
  • •What is my baseline VWF level, and how does it affect my personal bleeding risk for daily activities or surgeries?
  • •What is our concrete plan if I experience a severe nosebleed or a stubborn minor cut at home?
  • •How can we effectively manage heavy menstrual bleeding to ensure I do not develop iron-deficiency anemia?
  • •Should I be referred to a specialized Hemophilia Treatment Center (HTC) to coordinate my long-term comprehensive care?

Questions for You

4 questions

  • •Have I noticed any changes in how often or how severely I bleed from minor cuts, dental procedures, or menstruation?
  • •Do I know exactly which over-the-counter medications to avoid, and have I cleared my current pain relievers with my doctor?
  • •Am I clear on what to do and who to contact in a bleeding emergency?
  • •What are my main concerns about day-to-day life with a bleeding disorder, such as participating in sports, and have I discussed these with my care team?

References

References (24)
  1. 1

    Incidence of von Willebrand disease in Denmark, 1995-2016: A cohort study.

    Laursen ASD, Rasmussen TB, Chiu GR, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(2)):277-282 doi:10.1111/hae.14257.

    PMID: 33550641
  2. 2

    Von Willebrand's Disease.

    Leebeek FW, Eikenboom JC

    The New England journal of medicine 2016; (375(21)):2067-2080 doi:10.1056/NEJMra1601561.

    PMID: 27959741
  3. 3

    Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.

    Roberts JC, Malec LM, Halari I, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(1)):97-108 doi:10.1111/hae.14448.

    PMID: 34761486
  4. 4

    Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States.

    Michael Soucie J, Miller CH, Byams VR, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2021; (27(3)):445-453 doi:10.1111/hae.14263.

    PMID: 33780098
  5. 5

    Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program.

    Christopherson PA, Haberichter SL, Flood VH, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(7)):1576-1588 doi:10.1111/jth.15713.

    PMID: 35343054
  6. 6

    Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.

    Windyga J, Dolan G, Altisent C, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(5)):739-51 doi:10.1111/hae.12955.

    PMID: 27292438
  7. 7

    Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.

    Windyga J, Dolan G, Altisent C, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(1)):110-20 doi:10.1111/hae.12763.

    PMID: 26207933
  8. 8

    A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?

    Reardon B, Pasalic L, Favaloro EJ

    Biomolecules 2025; (15(7)) doi:10.3390/biom15070967.

    PMID: 40723839
  9. 9

    Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.

    Ragni MV, Rothenberger SD, Feldman R, et al.

    The Lancet. Haematology 2023; (10(8)):e612-e623 doi:10.1016/S2352-3026(23)00119-9.

    PMID: 37385272
  10. 10

    Transcutaneous auricular neurostimulation to reduce heavy menstrual bleeding in women with and without von Willebrand disease.

    Czura CJ, Weyand AC, Baldwin MK, et al.

    Frontiers in medicine 2025; (12()):1664433 doi:10.3389/fmed.2025.1664433.

    PMID: 41133152
  11. 11

    Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).

    Lissitchkov TJ, Buevich E, Kuliczkowski K, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(2)):152-162 doi:10.1097/MBC.0000000000000568.

    PMID: 27203734
  12. 12

    Von Willebrand Disease Epidemiology, Burden of Illness and Management: A Systematic Review.

    Du P, Bergamasco A, Moride Y, et al.

    Journal of blood medicine 2023; (14()):189-208 doi:10.2147/JBM.S389241.

    PMID: 36891166
  13. 13

    Retrospective chart review of GI bleeding in people with von Willebrand disease.

    Roberts JC, Escobar MA, Acharya S, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2024; (30(4)):970-980 doi:10.1111/hae.15034.

    PMID: 38751022
  14. 14

    Clinical Spectrum, Subtype Distribution, and Treatment Outcomes in von Willebrand Disease: A Prospective Study from a Hemophilia Treatment Center in Pakistan.

    Borhany M, Qureshi H, Ahmed NK, et al.

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2026; (32()):10760296261422757 doi:10.1177/10760296261422757.

    PMID: 41671171
  15. 15

    Effectiveness of long-term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease.

    Rugeri L, Harroche A, Repessé Y, et al.

    European journal of haematology 2022; (109(1)):109-117 doi:10.1111/ejh.13778.

    PMID: 35438801
  16. 16

    Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies.

    van Kwawegen CB, Leebeek FWG

    Research and practice in thrombosis and haemostasis 2024; (8(8)):102599 doi:10.1016/j.rpth.2024.102599.

    PMID: 39628990
  17. 17

    rVWF: treatment finally reaches the modern age.

    Metjian AD

    Blood 2015; (126(17)):1975-6 doi:10.1182/blood-2015-08-664052.

    PMID: 26494919
  18. 18

    Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.

    Federici AB, Santoro RC, Santoro C, et al.

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2024; (30()):10760296241264541 doi:10.1177/10760296241264541.

    PMID: 39033425
  19. 19

    Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report.

    Brown R

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(7)):570-575 doi:10.1097/MBC.0000000000000632.

    PMID: 28379876
  20. 20

    Von Willebrand's disease in breast surgery: case report.

    Rodríguez L, Monroy M, Guerrero ME, Villarroya N

    Journal of surgical case reports 2024; (2024(6)):rjae395 doi:10.1093/jscr/rjae395.

    PMID: 38835948
  21. 21

    A personalized approach to the management of VWD.

    Phua CW, Berntorp E

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2019; (58(5)):590-595 doi:10.1016/j.transci.2019.08.009.

    PMID: 31466808
  22. 22

    Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.

    Franchini M, Di Perna C, Santoro C, et al.

    Seminars in thrombosis and hemostasis 2016; (42(1)):36-41 doi:10.1055/s-0035-1564844.

    PMID: 26595151
  23. 23

    Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.

    Khatri NV, Patel B, Kohli DR, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(2)):278-282 doi:10.1111/hae.13419.

    PMID: 29446520
  24. 24

    von Willebrand disease: A guide for the internist.

    Kaur V, Elghawy O, Deshpande S, Riley D

    Cleveland Clinic journal of medicine 2024; (91(2)):119-127 doi:10.3949/ccjm.91a.22033.

    PMID: 38307601

This information about Von Willebrand Disease life expectancy is for educational purposes only. Always consult your hematologist or healthcare team regarding your personal bleeding risks and long-term treatment plan.

Get notified when new evidence is published on Von Willebrand Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.